DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients

Information source: Oregon Health and Science University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Liver Transplantation

Intervention: oral Valganciclovir vs oral Ganciclovir (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: Oregon Health and Science University

Official(s) and/or principal investigator(s):
Ali J Olyaei, PharmD, Principal Investigator, Affiliation: Oregon Health and Science University

Overall contact:
Ali J Olyaei, PharmD, Phone: 503-494-8132, Email: olyaeia@ohsu.edu

Summary

Null Hypothesis: There is no significant difference in the incidence of CMV infection when using oral valganciclovir or ganciclovir as prophylactic anti-viral therapy. Alternate Hypothesis: There exists a significant difference in the incidence of CMV infection when oral valganciclovir is used for CMV prophylaxis rather than oral ganciclovir. A formal hypothesis to be tested should be defined.

Clinical Details

Official title: Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients: A Single Center Experience With Oral Ganciclovir Versus Valganciclovir

Study design: Observational Model: Defined Population, Time Perspective: Cross-Sectional

Detailed description: The objective for this retrospective clinical study is to describe the incidence of CMV infection in orthoptic liver transplant recipients who receive oral valganciclovir or ganciclovir as their CMV prophylactic anti-viral therapy. Endpoints: Primary Endpoint CMV infection will be characterized as viremia, syndrome or disease by the abovementioned methods for up to one year post-transplantation. Secondary Endpoints 1. Patient and allograft survival based on donor/recipient CMV status 2. Incidence of graft rejection and loss associated with CMV infection 3. Time to hepatitis C virus (HCV) occurrence 4. Incidence of HSV, EBV and VZV reactivations 5. Severity of HCV occurrence based on biopsy reports based on the Knodell score 6. Safety and tolerability of oral valganciclovir and ganciclovir

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- All liver transplants will be performed at Oregon Health & Science University (OHSU)

and the OHSU surgical and medical staff will treat patients. Exclusion Criteria:

- Portland Veterans Affairs Medical Center liver transplant recipients

- Patients deceased within thirty days of receiving liver allograft

- Patients with low risk of acquiring CMV infection: donor-negative and

recipient-negative (D-/R-)

- Patients undergoing re-transplantation

- Lost to follow-up (minimum follow-up is 1 year)

- History of CMV infection or disease

- Anti-CMV therapy within the past 30 d

- Severe, uncontrolled diarrhea or evidence of malabsorption.

Locations and Contacts

Ali J Olyaei, PharmD, Phone: 503-494-8132, Email: olyaeia@ohsu.edu

Additional Information

Starting date: August 2006
Last updated: August 16, 2006

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017